Globe NewsWire News Distribution Service

Details

Written by Globe NewsWire Press Releases

Category: Globe NewsWire News Distribution Service

Published: 13 January 2025

Created: 13 January 2025

Last Updated: 13 January 2025

Enhances Lantheus’ growth profile with Neuraceq®, a globally approved F-18 PET imaging agent used to detect beta-amyloid plaques in patients evaluated for Alzheimer’s Disease Advances Lantheus’ radiopharmaceutical leadership with addition of Alzheimer’s radiodiagnostic commercial infrastructure, expanded pipeline, and enhanced R&D capabilities

Posted: 2025-01-13 05:05:00

Get Full News Story On GlobeNewsWire Press Release Service

Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

• Prev
• Next

Related News Stories From The Web And More

Related Bing News Search Results

Press Release: Lantheus to Acquire Life Molecular Imaging for an Upfront Payment of $350 Million to Accelerate Innovation for Patients in the Growing Alzheimer’s Disease Radiodiagnostic Market - Newscast

Lantheus to acquire Evergreen in $1bn deal to expand radiopharmaceutical pipeline

Thu, 30 Jan 2025 03:01:00 GMT Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...

Why Lantheus Holdings Stock Got Thrashed on Tuesday

Wed, 29 Jan 2025 01:30:04 GMT Well before market open that morning, Lantheus announced that it has signed a definitive agreement to acquire clinical-stage peer Evergreen Theragnostics. For its new asset, Lantheus will make an ...

Lantheus To Buy Evergreen Theragnostics For Over $1 Billion To Bolster Its Cancer Radiopharmaceutical Portfolio

Tue, 28 Jan 2025 07:32:00 GMT Lantheus strengthens its radiopharmaceutical business with Evergreen and Life Molecular acquisitions, adding oncology and Alzheimer's diagnostics.

Lantheus to Acquire Evergreen Theragnostics for $250 Million

Tue, 28 Jan 2025 07:02:00 GMT Lantheus ( ($LNTH) ) has shared an update. On January 27, 2025, Lantheus Medical Imaging, a subsidiary of Lantheus Holdings, announced an ...

Lantheus lays out $250M+ to get its hands on radiopharma developer and CDMO Evergreen

Tue, 28 Jan 2025 06:09:00 GMT On a quest to carve out a spot as one of the nuclear medicine greats, Massachusetts-based radiopharmaceutical specialist Lantheus is placing some serious cash on the dealmaking table. | In a ...